Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Debra Ainge

- PMLiVE

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The approval follows a failed phase 3 study, but the treatment showed promise in patients with SOD1-ALS

- PMLiVE

Macmillan and Big Health partnership to provide digital health apps to cancer patients

The partnership will potentially reduce NHS waiting lists for face-to-face therapy and expand patient options

- PMLiVE

Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC

Lung cancer is one of the most common cancers worldwide, with NSCLC making up 80-85% of all lung cancers

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on CLL

Spotlight on CLLAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in...

Medscape Education

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on Lymphoma

Spotlight on LymphomaAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Dr Loretta Nastoupil, US, on the most important abstracts to look out for in...

Medscape Education

- PMLiVE

Collaboration over complacency in reshaping the future of cardiovascular care

Interview with Oliver Appelhans

- PMLiVE

NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

The agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate

- PMLiVE

MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug

Oxybryta is the first treatment in Britain to directly block sickle haemoglobin polymerisation

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma

If approved by the EC, Opdualag would be the first LAG-3 blocking antibody combination available in Europe

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

AstraZeneca’s Tezspire recommended for approval in the EU by CHMP

The recommendation is for the treatment of severe asthma as an add-on therapy for patients 12 years and above

- PMLiVE

TECHNOLOGY TRENDS AND THE FUTURE OF MEDICAL DEVICES

A MEDSCAPE DIGITAL HEALTH AND INNOVATION EVENT

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links